NEW YORK – Inex Innovate today announced a distribution deal with Inalways to offer its OvaCis test for ovarian cancer in Taiwan.
OvaCis is a CE-IVD marked in vitro diagnostic that can be used to assess epithelial ovarian cysts. Singapore-based Inex Innovate introduced the test for clinical use in 2016. The company has pledged to make it available in other Asian markets. By partnering with Taipei-based Inalways, Inex Innovate gains access to 18 medical centers and about 100 teaching hospitals in Taiwan.
Inex Innovate CEO Kane Black said in a statement that the deal should "improve patient outcomes, reduce operating theater times, and impact positively on costs for the patient, health system and insurers in the Taiwanese healthcare system."
OvaCis is a colorimetric assay that can be used to assess ovarian cyst fluid for the biomarker haptoglobin during an endoscopic cystectomy. The biomarker is considered to be indicative of early-stage ovarian cancer, and the company has positioned the test as an alternative to frozen section.
Inex Innovate is the result of last year's $72 million merger of Nova Satra Dx and Inex Innovations and Exchange, two Singaporean molecular diagnostics firms. The company intends to begin selling other tests across Asia, including NovoTect Bc, a test for stratifying breast cancer patients.